A synthetic peptide with anti-platelet activity derived from a CDR of an anti-GPIIb-IIIa antibody  by Jarrin, Annie et al.
FEBS Letters 354 (1994) 169-172 
FEBS 14726 
A synthetic peptide with anti-platelet activity derived from a CDR of 
an anti-GPIIb-IIIa antibody 
Annie Jarrin, Annie Andrieux, Agnb Chapel, Thierry Buchou, GCrard Marguerie 
CEA, Laboratoire d’hkmatologie, INSERM U217, DBMS, CENG, 38054 Grenoble cedex 9, France 
Received 1 September 1994 
Abstract A monoclonal antibody, AC7, directed against the RGD (Arg-Gly-Asp) binding site on the GpIIIa subunit of the platelet fibrinogen 
receptor, interacts only with activated platelet. In order to identify the regions of AC7 that interact with the receptor, cDNA sequences of AC7 
immunoglobulin heavy and light chain variable regions were determined. Among the six complementarity-determining re ions (CDRs) of AC7, the 
CDR3 heavy chain (H3) contains homology to the RGDF sequence within fibrinogen. A synthetic peptide ncompassing the H3 region (H3, 
RQMIRGYFDV) inhibited platelet aggregation a d fibrinogen binding to platelet (IC,, = 7OOpM). The inhibitory potencies of modified H3 peptides 
suggest hat the RGYF sequence within the H3 peptide mimic the receptor ecognition sequence in fibrinogen. 
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1. Introduction 
Binding of fibrinogen to its platelet receptor, the GpIIb-IIIa 
complex, depends on platelet activation by agonists such as 
ADP, thrombin or collagen; a process required for platelet 
aggregation. Fibrinogen binding to this glycoprotein is medi- 
ated in part by Arg-Gly-Asp-like sequences [l]. The RGD bind- 
ing domain of GP IIb-IIIa has been localized in a fragment of 
the GPIIIa subunit that includes the sequence between amino 
acids 109171 [2]. 
A murine monoclonal antibody, AC7 (IgM), has been pro- 
duced against a synthetic peptide derived from the GPIIIa 
subunit (residues 109-128) and was shown to interact with 
platelets treated by a stimulus such as ADP. AC7/‘activated 
platelets interaction was inhibited by fibrinogen and RGD con- 
taining peptides. 
Moreover, AC7 has been described to inhibit fibrinogen 
binding to its receptor and platelet aggregation in a dose-de- 
pendent fashion [3]. In order to characterize the structural 
features of AC7 responsible for its ability to inhibit platelet 
GpIIb-IIIa functions, we sequenced the heavy and light chain 
variable regions of AC7 immunoglobulin cDNAs, derived 
from AC7 mRNAs using a reverse-transcription polymerase 
chain reaction (RT-PCR) procedure. We assumed that amino 
acid sequences within the complementarity-determining- 
regions (CDRs) of the AC7 antibody could account for AC7 
activity. 
In this report we show that the CDR3 heavy chain (H3) of 
AC7 contains an RGYF motif which possesses tructural and 
functional homology with the RGDF fibrinogen derived-pep- 
tide. 
*Corresponding author. Fax: (33) 76 88 51 23. 
Abbreviations: GpIIb-IIIa, glycoprotein IIb-IIIa; cDNA, complemen- 
tary deoxyribonucleic acid; mRNA, messenger ribonucleic acid; SDS, 
sodium dodecyl sulfate. 
2. Materials and methods 
2.1. Polymerase chain reaction 
Cytoplasmic RNAs were purified from the AC7 hybridoma cell line 
[4]. Immunoglobulin mRNAs were specifically reverse-transcribed 
using 3’ primers located on murine immunoglobulin heavy chain CHl 
gene (amino acid residues 558-587, S-GGGAGACAGCAA- 
GACCTGCGAGGTGGCTAG-3’, CHI) or on murine immunoglob- 
ulin light chain CK gene (residues 459-488, 5’-ACTGTTCAG- 
GACGCCATTTTGTCGTTCACT-3’, CK). Primer sequences were 
designed to maximize homologies with published sequences [5] of p 
heavy and K light chains of mouse immunoglobulin groups. Heavy 
chain variable region amplification by polymerase chain reaction 
(PCR) was Performed using a 3’ primer (residues 41W3, S-GA- 
AGTCCCGGGCCAGGCAGCCCATGGCCAC-3’, VHl) and a 5 
primer (residues 2-23, S-GGCTGCAGAGGTCIGAlCAAlGCTG~ 
TCAGWGAGTCWTGG-3’, VH2 containing a PstI restriction site 
-underlined). Light chain variable region was amplified using the 3 
primer CKl and a 5’ primer (residues l-24, S- CCGGATCCGACA- 
TTCAGCTGACCCAGTCTCCA-3’, VKl contain-HI re- 
striction site - underlined). PCR products were then used for a second 
amplification procedure. A 3’ internal VH primer (residues 312-345,5’- 
GGATCGATTGAGGAGACGGTGACCGTGGT-3’, VH3 contain- 
ing a CZaI restriction site - underlined) and a 5’ primer (residues l-23, 
S-GGCTGCAGCAGGTGCAGCTGAAGCAGTCAGG-3’, VH4 
containing a PstI restriction site - underlined) were used for amplifica- 
tion of the heavy chain variable region. The second ‘light chain variable 
region amplification’ was performed using a 3’ internal primer (residues 
302324, 5’-TCGAATTCGTTAGATCTCCAGCTTGGTCCCJ, 
VK2 containing an EcoRI restriction site - underlined) and the 5 
primer VKl. All oligonucleotide primers were made on Pharmacia 
Cyclone synthetizer using phosphoramidite chemistry. 
The second generated PCR products were digested with appropriate 
restriction enzymes, agarose gel-purified, subcloned into pBlue Script 
and sequenced on both strand by the chain termination method using 
the Sequenase kit (United States Biochemical Corp). 
2.2. Microsequencing 
After electrophoresis in SDS-polyacrylamide gel (10% SDS-PAGE) 
of purified AC7 immunoglobulin treated with 2% of /3-mercaptoetha- 
nol, proteins were transferred onto an immobilon PVDF membrane 
(Millipore) according to the method of Matsudaira [6]. The N-terminal 
amino acid sequence of both K light and p heavy chains were deter- 
mined by automated Edman degradation methodology using an ABl 
Mode 470A sequenator (Applied Biosystem). 
2.3. Synthetic peptides 
Synthetic peptides were obtained by solid-phase synthesis using an 
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Applied Biosystems synthesizer. The peptides were more than 95% 
homogeneous when analyzed by high pressure liquid chromatography 
on a C18-0DS2 cohmm eluted with a O-80% linear gradient of acetoni- 
bile in 0.1% trifluoroacetic acid. The amino acid composition of each 
peptide was consistent with its amino acid sequence. 
2.4. Aggregation experiments 
Platelets were isolated from fresh human blood drawn into acid/ 
citrate/dextrose by ditTerentia1 centrifugation followed by gel filtration 
in a modified Tyrode buffer, pH 7.2, containing 2% bovine serum 
albumin (Calbiochem). Platelets (2 x lO’/ml) in 360 ,~l of Tyrode buffer 
+ 0.5 mM CaCl, were incubated, without stirring, in the presence of 
peptides. After incubation for 5 min, ADP (10 PM) and fibrinogen (0.1 
PM) were added and aggregation was recorded at 37“C with a stirring 
rate of 1,000 rpm using a Payton dual-channel aggregometer (AHS, 
Strasbourg, France). 
2.5. Binding experiments 
Human fibrinogen was obtained by differential ether fractionation, 
as previously described [7]. Purified human fibrinogen was radiolabeled 
with carrier-free [‘251]Na (Amersham) using a modified chloramine-T 
procedure [8]. After removal of free iodine by filtration on P-20 column 
(Pharmacia) with phosphate buffer saline, the specific activity ranged 
from 0.5 to 2 &i/pg of fibrinogen. The precipitability of radiolabeled 
fibrinogen in 10% thrichloroacetic acid was greater than 94%. Binding 
of radiolabeled fibrinogen to platelets was performed with lo8 cells/ml 
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Fig. 1. Nucleotide and amino acid sequences of light and heavy variable regions of AC7 immunoglobulin. Nucleotide sequences of light (a) and heavy 
(b) variable regions of AC7 immunoglobulin were determined as described in section 2. The sequences were segregated into complementarity- 
determining regions (CDRs, boxes). Deduced amino acid sequences are shown using single letter amino acid code. N-terminal amino acid sequences 
determined by microsequencing are underlined (for details, see section 2). Comparison of amino acid sequences was performed using a ‘Bisance’ 
program. 
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in the presence of 0.5 mM calcium and 10 PM ADP. After 30 min of 
incubation, the bound ligand was separated from the free ligand by 
centrifugation f80 ~1 samples through a15% sucrose inTyrode buffer 
and the radioactivity associated with platelets was quantified. 
3. Results 
3.1. The CDR3 of the AC7 heavy chain contains a motifsimilar 
to the fibrinogen A chain sequence 
Light and heavy chain variable regions nucleotide sequences 
of AC1 immunoglobulin are listed along with the predicted 
amino acid sequences (Fig. 1). AC7 K light and p heavy varia- 
ble regions belong to class IV and III of mouse K and,u variable 
regions, respectively. Since, NSl myeloma used for AC7 hy- 
bridoma production possess its own, but not secreted K light 
chain immunoglobulin, AC7 K light chain sequence was con- 
firmed by N-terminal microsequencing (N-terminal microse- 
quencing has been also monitored for the AC7 p heavy variable 
region and confirmed nucleotide sequence data). The only sim- 
ilarity between AC7-K or AC7-p sequences and fibrinogen was 
found in the CDR3-p. This CDR3 sequence (RQ- 
MIRGYFDV) possesses analogy with the RGDF region of 
fibrinogen Aa chain, known as efficient inhibitor of AC7/plate- 
let interaction [3]. This peptidic sequence was named H3 and 
further analyzed. 
3.2. A synthetic peptide corresponding to H3 inhibits platelet 
aggregation and fibrinogen binding to platelets 
In order to test the prediction that the QMIRGYFDV se- 
quence within the AC7 heavy chain CDR3 plays a role in the 
recognition of AC7 immunoglobulin with the ‘activated’ fibrin- 
ogen receptor (GpIIb-IIIa), we synthetized a lo-residue peptide 
(H3: RQMIRGYFDV), and tested its ability to inhibit platelet 
aggregation (Fig. 2) and fibrinogen binding (Fig. 3) to ADP- 
stimulated platelets. H3 peptide inhibitory effect on platelet 
aggregation correlates with the inhibition of fibrinogen binding 
which results in a ICsO of 700,~M. The remaining CDR-derived 
peptides (Hl, H2, Kl, K2, K3) did not induced any inhibition 
of platelet activity. Inhibition of fibrinogen binding by RGDF 
was analyzed for comparison and the GRGESP peptide was 
used as a negative control [9]. 
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Fig. 2. Inhibition of platelet aggregation by H3 peptide. Aggregations 
were performed with platelets (2.10’ cells/ml) in the presence of0.5 mM 
CaCl,. Platelets were incubated in the presence or in the absence (con- 
trol) of 1 mM H3 (RQMIRGYFDV) or 1mM negative control peptide 
(GRGESP). After 5 min, aggregations were initiated by adding 10pM 
ADP, 0.1 PM fibrinogen and stirring. 
3.3. Modifications of H3 peptide affect its inhibitory effect 
Specific roles of sequences present into the H3 peptide are 
listed in Table 1. Deletion of the N-terminal portion of the 
H3 peptide (dH3 Y) reduced strongly its inhibitory effect on the 
binding of fibrinogen to ADP-stimulated platelets (dH3 Y, ICrO 
of 2,200 PM instead of 700 PM for H3 peptide). However, the 
central portion of the H3 peptide plays an important role: 
substitution of tyrosine (Y) to glycine (G) in the dH3 Y peptide 
produces an inactive coumpound (any inhibition is obtained 
even at 2 mM), while replacing tyrosine (Y) to aspartic acid 
(D) increased the inhibitory effect of the dH3 Y peptide 
(IC,, = 12 ,uM). 
4. Discussion 
The results presented in this report suggest that the 
RGYFDV sequence, within the CDR3 heavy chain variable 
region of AC7 IgM immunoglobulin mimics the RGD platelet 
receptor (GpIIbIIIa) recognition sequence in fibrinogen. How- 
ever, this sequence was less potent than the antibody itself 
Fig. 3. Inhibition of [“‘I]fibrinogen binding to ADP-stimulated platelets by H3 peptide. 10 PM ADP, 0.1 PM [‘251]fibrinogen andvarious concentra- 
tions of H3 (A), RGDF (0) or Fibrinogen binding was performed on platelets (10’ cells/ml) in the presence of0.5 mM CaCl,, GRGESP peptides 
(+). The GRGESP and RGDF peptides were used as negative and positive control, respectively. 
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Table 1 
Inhibition of [‘251]fibrinogen binding to ADP-stimulated platelets by 
modified H3 peptides 
Peptide Inhibition of [rz51]fibrinogen binding 
(IC 50) PM 
H3: RQMIRGYFDV 700 
A H3 y: RGYFDV 2,200 
A H3 Y+G: RGGFDV ND 
A H3 Y+D: RGDFDV 12 
Binding experiments were performed as described in Fig. 3. 
(ICso = 700 PM for the RQMIRGYFDV peptide versus 
IC50 = 105 nM for AC7 immunoglobulin for the binding of 
fibrinogen) [3]. 
An other IgM murine monoclonal antibody (PAC-l), that 
also inhibits fibrinogen binding to platelet [lo] has been de- 
scribed to possesse an active RYD motif in its heavy chain 
CDR3 [ 1 I]. This sequence corresponds to the germline D gene 
DSP 2.10 and is assumed to determine the specificity of PAC-1 
for fibrinogen receptor. Tomiyama and co-workers 121 studied 
extensively others antibodies that contains the same RYD- 
containing germline D gene DSP 2.10. As these antibodies show 
different affinities for GpIIb-IIIa, the authors concluded that 
the RGD-like sequence orientation and therefore accessibility 
into the different constrained CDR3 heavy chain variable re- 
gion of the corresponding antibodies define their function. 
Moreover, NMR studies of constrained RGD containing pep- 
tides suggested that the RGD potency depends on conforma- 
tion [3]. 
We report here the sequence of an analoguous anti GpIIb- 
IIIa antibody (AC7) which does not contain the RYD-contain- 
ing DSP 2.10 sequence but exibits another RGD-like sequence 
(RQMIRGYFDV) in the corresponding CDR. It should be 
noted that the RQMIRGYFDV sequence within the whole 
AC7 immunoglobulin is folded as a constrained j%turn and 
interacts with other CDRs to form the binding recognition site 
A. Jarrin et al. IFEBS Letters 354 (1994) 169-172 
of platelet fibrinogen receptor. Thus, knowledge of the tridi- 
mentional structure of AC7 heavy chain CDR3 within the en- 
tire immunoglobulin should lead to potent inhibitors of throm- 
bosis. 
These sequences are available from the EMBL data library 
under Accession Numbers X79553 (heavy chain) and X79554 
(light chain). 
Acknowledgments: We are grateful to J. Garin and M. Vincon for 
microsequencing. 
References 
[l] Plow, E.F., Pierschbacher, M.D., Ruoslahti, E., Marguerle, G.A. 
and Ginsbere. M.H. (1985) Proc. Natl. Acad. Sci. 82, 8057-8061. 
PI 
[31 
141 
[51 
F-i 
VI 
PI 
[lOI 
Pll 
WI 
v31 
D’Souza, SE., Ginsberg, ‘M.H., Burke, T.A., Lam, S.C.T. and 
Plow E.F. (1988) Science 242, 91-93. 
Andrieux, A., Rabiet, M.J., Chapel, A., Concord, E. and 
Marguerie, G. (1991) J. Biol. Chem. 266, 14202-14207. 
Got@, N.M. (1988) Anal. Biochem. 173, 93-95. 
Kabat, E.A., Wu, T.T., Reid-Miller, M., Perry, H.M. and Gottes- 
man, K.S. (1987) Sequences ofProteins of Immunologic Interest, 
United States Dent. of Health and Human Services, Public Health 
Service, National Institutes of Health. 
Matsudaira. P. (1987) J. Biol. Chem. 262. 10035-10038. 
Kekwick, B.A.,‘Mc Kay, M.E., Nance, M.H. and Record, B.R. 
(1955) Biochem. J. 60, 671-683. 
MC Conahey, P. and Dixon, F. (1986) Int. Arch. Allergy. 29, 
185189. 
Tranoui, L., Andrieux, A., Hudry-Clergeon, G., Ryckewaert, J.J., 
Soyerl S:, Chapel, A., Ginsberg, M.H., Plow, E.F. and Marguerie, 
G. (1989) J. Cell. Biol. 108. 2519-2527. 
Shattil, S.J., Hoxie, J.A., Cunningham, J.A. and Brass, L.F. (1985) 
J. Biol. Chem. 260, 11107-11114. 
Taub, R., Gould, R.J., Garsky, V.M., Ciccarone, T.M., Hoxie, J., 
Friedman. P.A. and Shaltil, S.J. (1989) J. Biol. Chem. 264, 259- 
265. 
Tomiyama, Y., Brojer, E., Ruggeri, Z.M., Shattil, S.J., Smiltreck, 
J.. Gorski. J.. Kumar. A.. Kieber-Emmons, T. and Kunicki, T.J. 
(1992) J. Biol. Chem.‘267, 18085-18092. 
Lazarus, R.A. and McDowell, R.S. (1993) Cur. Opin. Bioteh. 4, 
438445. 
